Bionomics Limited, (BNOX): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
BNOX Stock Price Chart Interactive Chart >
BNOX Price/Volume Stats
|Current price||$7.56||52-week high||$22.00|
|Prev. close||$8.45||52-week low||$5.70|
|Day high||$7.56||Avg. volume||5,999|
|50-day MA||$9.58||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||42.32M|
Bionomics Limited, (BNOX) Company Bio
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Most Popular Stories View All
BNOX Latest News Stream
|Loading, please wait...|
BNOX Latest Social Stream
View Full BNOX Social Stream
Latest BNOX News From Around the Web
Below are the latest news stories about Bionomics Limited that investors may wish to consider to help them evaluate BNOX as an investment opportunity.
ADELAIDE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), today announced its half-year report for the half-year ended 31 December 2021. The half-year ending 31 December 2021 represented a transformational period for Bionomics in which the Company made great strides on multiple fronts including the areas of pipeline progress and advancements, capital raising and implementation of corporate strategic initiatives getting the Company back on a renewed value-
Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022
Bionomics Limited (Nasdaq: BNOX, ASX: BNO), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, will ring the Nasdaq Closing Bell remotely from around the globe.
Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022.
Analysts Offer Insights on Healthcare Companies: ObsEva SA (OBSV), Bionomics Ltd ADR (BNOX) and Xilio Therapeutics (XLO)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV – Research Report), Bionomics Ltd ADR (BNOX – Research Report) and Xilio Therapeutics (XLO – Research Report) with bullish sentiments. ObsEva SA (OBSV) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA, with a price target of $15.00. The company's shares closed last Friday at $1.94, close to its 52-week low of $1.93. According to TipRanks.
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States
Bionomics Limited (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the issuance of 243,300 American Depositary Shares (ADSs), each representing 180 ordinary shares of Bionomics, pursuant to the exercise in full of the underwriters' option to purchase additional ADSs in connection with the Company's previously announced initial public offering in the United States (the Offering). The ADSs were sold at a public offering price of US$12.35 per ADS.
BNOX Price Returns